On Tuesday, the FDA accepted for review Capricor Therapeutics Inc’s (NASDAQ:CAPR) Biologics License Application for ...

Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with calls leading puts 19:7. Implied volatility suggests the market is ...

Capricor Therapeutics, Inc.'s Deramiocel receives FDA Priority Review for DMD cardiomyopathy, with a decision by Aug. 2025.

Highlights,Capricor Therapeutics is a biotechnology company specializing in the development of treatments for rare disorders.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pliant Therapeutics (PLRX – Research Report) and Capricor ...

Shares of Capricor Therapeutics (CAPR) closed Tuesday with modest gains and rose more than 3% in extended trading after the ...

Capricor Therapeutics' shares rose after its biologics license application for deramiocel to treat a form of muscular dystrophy was given priority review by the Food and Drug Administration. Shares ...

The Food and Drug Administration has accepted Capricor Therapeutics' application seeking approval of its cell therapy deramiocel for muscular dystrophy patients and granted it a priority review. The ...

Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) saw unusually large options trading activity on Monday. Traders bought 4,400 call options on the stock. This is an increase of 37% compared to ...

In addition to the Priority Review, deramiocel has received Orphan Drug Designation from the FDA and EMA, as well as RMAT and ATMP Designations in the U.S. and Europe, respectively. Furthermore, ...

Capricor Therapeutics Stock Down 11.1 % Shares of CAPR stock opened at $13.67 on Tuesday. The stock has a market cap of $621.57 million, a PE ratio of -12.90 and a beta of 4.08.

PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy.